By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Singulex, Inc. 

1701 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-814-9000 Fax: 510-814-9018


About Singulex, Inc.

Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics. Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit

About Singulex’s Erenna Platform

Powered by Single Molecule Counting (SMC™) technology, Singulex’s Research-Use-Only Erenna® Immunoassay System’s ability to measure small changes in biomarkers such as cardiac troponin I and cytokines, and to monitor these changes over time, has expanded the clinical utility of established markers. The Erenna system helps power the discovery and development of innovative lab developed tests and treatments for chronic diseases such as cardiovascular disease, Alzheimer’s disease, oncology, rheumatoid arthritis and diabetes.

Key Statistics

Ownership: Private

Web Site: Singulex


Company News
Singulex Receives New, Broad Patent For Digital Detection Of Cardiac Troponin-I Or Cardiac Troponin-T For Coronary Artery Disease Rule-Out 9/8/2017 7:27:56 AM
Singulex Expands Diagnostics Partnerships, Looks for FDA Approval of Sgx Clarity System Next Year 9/5/2017 5:48:55 AM
Evaluations Of The Analytical Performance Of The Singulex Cardiac Troponin I Assay Used On Its Single Molecule Counting Technology Platform Demonstrates Ability To Improve Cardiovascular Disease Rule-Out 8/2/2017 11:13:40 AM
Ultra-Sensitive C. Difficile Assay In Development By Singulex Demonstrates Potential To Improve Diagnosis In Pilot Studies 6/6/2017 7:49:32 AM
Singulex Release: First Ultra-Sensitive Cardiac Troponin (cTnI) Test Using Single Molecule Counting Technology Receives CE Mark 6/1/2017 12:46:22 PM
Singulex Announces $50 Million Senior Secured Debt Facility With Perceptive Advisors 4/17/2017 7:54:31 AM
Singulex Announces CE Mark For Sgx Clarity System 4/3/2017 7:59:52 AM
Singulex Expands Collaboration With European Clinical Laboratories To Demonstrate Applications And Opportunity Of Sgx Clarity System 3/23/2017 8:36:20 AM
Singulex Release: Diagnostic Company Enters Into Collaboration With QIAGEN N.V. (QGEN) To Develop Companion Diagnostics 1/10/2017 7:54:59 AM
Singulex Opens European Office And Advances IVD System Evaluation 12/20/2016 12:00:47 PM